Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.67 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.67 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.67 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.67 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.65 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.65 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.65 |
| ▸ | HTR3B | O95264 | 1/20 | 0.65 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.65 |
| ▸ | CHRNG | P07510 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.65 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14235482 | 1.00 | CHRNB2 (0.67) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL10079075 | 0.94 | CHRNB2 (0.66) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL12090442 | 0.93 | CHRNB2 (0.64) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL27892475 | 0.88 | CHRNA7 (0.50) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5553140 | 0.84 | CHRNB2 (0.59) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL30089417 | 0.80 | CHRNA7 (0.64) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL15836592 | 0.80 | CHRNB2 (1.00) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL155935 | 0.80 | CHRNB2 (1.00) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL13238778 | 0.80 | CHRNB2 (1.00) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| (+/-)Nicotine SCHEMBL10909353 | 0.79 | ALDH1A1 (1.00) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230404915-A1 | RAPIDLY DISINTERGRATING COMPOSTIONS AND METHODS (Nicotine) | Orcosa Inc. (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4243771-A1 | RAPIDLY INFUSING COMPOSITIONS AND METHODS | Orcosa Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| EP-3250209-B1 | COMT INHIBITING METHODS AND COMPOSITIONS | LIEBER INST FOR BRAIN DEVELOPMENT (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022104059-A1 | RAPIDLY INFUSING COMPOSITIONS AND METHODS | Orcosa Inc. (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| EP-3041841-B1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2019-06-05 | — | — | EP | disclosed |
| US-10035799-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2018-07-31 | — | — | US | disclosed |
| US-20090215761-A1 | QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | CYLENE PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| EP-1874731-A4 | QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | CYLENE PHARMACEUTICALS INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-7402579-B2 | Quinobenzoxazine analogs and compositions | CYLENE PHARMACEUTICALS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1874731-A2 | QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | Cylene Pharmaceuticals, Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070287704-A1 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-13 | — | — | US | disclosed |
| US-20070287704-A1 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-13 | — | — | US | disclosed |
| WO-2007135026-A2 | SUBSTITUTED PTERIDINES AS THERAPEUTIC AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-29 | — | — | WO | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20060264634-A1 | Quinobenzoxazine analogs and methods of using thereof | CYLENE PHARMACEUTICALS, INC. | 2006-11-23 | — | — | US | disclosed |
| WO-2006113509-A2 | QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | CYLENE PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264634-A1 | Quinobenzoxazine analogs and methods of using thereof | CYP2W1, NQO2, UGT2B7 | CHRNB2 1408/4885CHRNA7 1897/4885CHRNA4 2144/4885 |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | CHRNB2 4733/4885CHRNA7 4356/4885CHRNA4 4631/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | CHRNB2 3404/4885CHRNA7 3843/4885CHRNA4 3102/4885 |
| US-20070287704-A1 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE4C | CHRNB2 2596/4885CHRNA7 1546/4885CHRNA4 990/4885 |
| US-10035799-B2 | COMT inhibiting methods and compositions | COMT, SLC6A3, MAOA | CHRNB2 223/4885CHRNA7 303/4885CHRNA4 341/4885 |
| US-20090215761-A1 | QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | CYP2W1, NQO2, UGT2B7 | CHRNB2 1408/4885CHRNA7 1897/4885CHRNA4 2144/4885 |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | CHRNB2 2141/4885CHRNA7 2234/4885CHRNA4 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.